FDA
-
-
-
-
-
-
-
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposiumâ„¢ 2026
-
-
-
-
-
-
-
Barclays Downgrades Sangamo BioSciences (SGMO) to Equalweight
-
-
-
-
-
-
-
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
-
-
-
-
-
-
-
Sangamo Therapeutics (SGMO) Announces FDA Clearance of IND Application for ST-503
-
-
-
-
-
-
-
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results
-
-
-
-
-
-
-
Sangamo Therapeutics (SGMO) Announces Updated Phase 1/2 STAAR Study Data
-
-
-
-
-
-
-
Sangamo Therapeutics Announces Strategic Update and Reports Preliminary First Quarter 2023 Financial Results
-
323,582 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

